NCT00426049Unknown3 期
Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease
German Heart Institute2 个研究点 分布在 1 个国家目标入组 484 人开始时间: 2006年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 484
- 试验地点
- 2
- 主要终点
- Major adverse cardiac events (MACEs)within 6 months
研究概览
简要总结
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant coronary artery disease. The aim is to reduce Major Adverse Cardiac Events (MACEs) including death, coronary artery bypass grafting (CABG) to the target vessel, Q-wave and non-Q-wave myocardial infarction, and target lesion revascularization within the first 6 months after intervention. Additionally safety and tolerability of Everolimus at the selected dose in this patient population will be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females, aged >18 years.
- •Patients with coronary artery disease who are scheduled for coronary intervention with bare metal stent placement for treatment of de novo or first restenosis in a native coronary artery.
- •Target lesion must be in a native coronary vessel of 2.25 - 4.0 mm size.
- •Target lesion has to be of less than or equal to 25 mm length.
- •Tandem lesion may be included as long as:
- •overall length is less than or equal to 25 mm
- •tandem lesion will be treated with one stent and counted as one lesion.
排除标准
- •The following exclusion criteria must not be present at Baseline visit 1 (BL1, Screening visit prior to coronary intervention). If an exclusion criterion occurred afterwards, e.g., during the coronary intervention, the patient must be excluded from the study.
- •Target lesion has a reference vessel size of less than 2.25 or more than 4.0 mm diameter.
- •Target lesion is a total occlusion or located at a bifurcation.
- •Treatment affords implantation of more than one stent per treated lesion.
- •Target lesion was already treated by brachytherapy.
- •Target lesion has one or more of the following criteria:
- •Left main lesion
- •Ostial lesion of the RCA
- •Located at less than 2 mm after the origin of the LAD or RCX.
- •Other protocol defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Major adverse cardiac events (MACEs)within 6 months
次要结局
- TLR and TVR after 6 months
- Drug safety and tolerability for 6 months
- Quantitative angiographic observations within the vessel after 6 months
- MACEs within 30 days
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial InfarctionMyocardial InfarctionNCT02672267Altaco XXI, LLP50
已完成
1 期
Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy AdultsCholera Vaccination ReactionNCT05559983International Vaccine Institute150
已完成
1 期
A Single Ascending Dose Study of ACT-541468 in Healthy Male SubjectsHealthy SubjectsNCT02919319Idorsia Pharmaceuticals Ltd.40
进行中（未招募）
1 期
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male ParticipantsHealthy ParticipantsNCT06517914Yuhan Corporation94
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy SubjectsHealthy VolunteersNCT04497662Kiniksa Pharmaceuticals, Ltd.52